Table of Contents

1. Methodology and Scope

1.1. Market Segmentation & Scope
1.1.1. Segment scope
1.1.2. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. Internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.4.1. Data analysis models
1.5. Market Formulation & Validation
1.6. Model Details
1.6.1. Commodity flow analysis (Model 1)
1.6.1.1. Approach 1: Commodity flow approach
1.7. Research Assumptions
1.8. List of Secondary Sources
1.9. List of Primary Sources

2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Type outlook
2.2.2. Application outlook
2.3. Competitive Insights

3. Japan Blood Plasma Market Variables, Trends & Scope

3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.2. Market restraint analysis
3.3. Japan Sports Medicine: Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.2. PESTLE Analysis
3.4. Regulatory Framework

4. Japan Blood Plasma Market Segment Analysis, By Type, 2024- 2032 (USD Million)

4.1. Definition and Scope
4.2. Type Market Share Analysis, 2024- 2032
4.3. Segment Dashboard

4.4. Japan sports medicine market, By Type, 2024- 2032

4.1. Albumin
4.1.1. Albumin market estimates and forecasts, 2024- 2032 (USD million)
4.2. Factor VIII
4.2.1. Factor VIII market estimates and forecasts, 2024- 2032 (USD million)
4.3. Factor IX
4.3.1. Factor IX market estimates and forecasts, 2024- 2032 (USD million)
4.4. Immunoglobulin
4.4.1. Immunoglobulin Market estimates and forecasts, 2024- 2032 (USD million)
4.5. Hyperimmune Globulin
4.5.1. Hyperimmune Globulin market estimates and forecasts, 2024- 2032 (USD million)
4.6. Others
4.6.1. Others market estimates and forecasts, 2024- 2032 (USD million)

5. Japan Blood Plasma Market Segment Analysis, By Application, 2024- 2032 (USD Million)

5.1. Immunodeficiency Diseases
5.1.1. Immunodeficiency Diseases market estimates and forecasts, 2024- 2032 (USD million)
5.2. Primary immunodeficiency
5.2.1. Primary immunodeficiency market estimates and forecasts, 2024- 2032 (USD million)
5.3. Hemophilia
5.3.1. Hemophilia market estimates and forecasts, 2024- 2032 (USD million)

6. Competitive Landscape

6.1. Recent Developments & Impact Analysis, By Key Market Participants

6.2. Company Categorization
6.3. Company Profiles
6.3.1. Takeda Pharmaceutical
6.3.1.1. Company overview
6.3.1.2. Financial performance
6.3.1.3. Type benchmarking
6.3.1.4. Strategic initiatives
6.3.2. Japan Blood Products Organization (JBPO)
6.3.2.1. Company overview
6.3.2.2. Financial performance
6.3.2.3. Type benchmarking
6.3.2.4. Strategic initiatives
6.3.3. KM Biologics (Meiji Group)
6.3.3.1. Company overview
6.3.3.2. Financial performance
6.3.3.3. Type benchmarking
6.3.3.4. Strategic initiatives
6.3.4. Mitsubishi Tanabe Pharma
6.3.4.1. Company overview
6.3.4.2. Financial performance
6.3.4.3. Type benchmarking
6.3.4.4. Strategic initiatives
6.3.5. Green Cross Corporation
6.3.5.1. Company overview
6.3.5.2. Financial performance
6.3.5.3. Type benchmarking
6.3.5.4. Strategic initiatives
6.3.6. Others
6.3.6.1. Company overview
6.3.6.2. Financial performance
6.3.6.3. Type benchmarking
6.3.6.4. Strategic initiatives

7 Japan Blood Plasma Market - Industry Analysis

7.1 Drivers, Restraints, and Opportunities
7.1.1 Overview
7.1.2 Drivers
7.1.2.1. Growth in Therapeutic Treatments
7.1.3 Restraints
7.1.3.1. Alternatives and Regulatory and Safety Concerns
7.1.4 Opportunities
7.1.4.1. Growth in Plasma Fractionation Facilities
7.2 Porters Five Forces Analysis
7.2.1 Overview
7.2.2 Bargaining Power of Buyers
7.2.3 Bargaining Power of Suppliers
7.2.4 Degree of Competition
7.2.5 Threat of New Entrants
7.2.6 Threat of Substitutes
7.3 Value Chain Analysis

8 Appendix